

VOLUME 72, 2002 KEYWORD INDEX

- γ activity, 669
Abuse liability, 559
Acetaldehyde, 55, 389
Acetylcholine, 117, 319, 457
Acetylcholinesterase inhibitors, 835
Acetylcholinesterase, 835, 881
Acquisition, 313
ACTH, 397
Activity levels, 151
Activity, 335, 581, 857
Acupuncture, 847
Acute dependence, 87
Acute effects, 953
Acute phase response, 143
Acute, 291
Addiction, 87
Adenosine A₁ receptor subtype, 23
Adenosine A_{2A} receptor subtype, 23
Adenosine, 569
ADHAlcohol dehydrogenase, 389
Adiposity signal, 423
Adolescent, 443
Adrenoceptor antagonists, 203
Adrenomedullary, 847
 β -adrenoceptors, 229
 β_1 -adrenoceptor, 465
 α_1 -Adrenoceptor antagonist, 365
Aged rats, 45
Aggression, 681
Aging, 913
Agmatine, 551, 873
Agonist efficacy, 803
Agonist, 291
Agouti-related protein, 491
Alcohol abuse, 601
Alcohol dependence, 601
Alcohol preference, 475
Alcohol, 5, 151, 335, 355, 475, 601
Alcohol-preferring rats, 55, 491
Alcoholism, 521, 601
Aldehyde dehydrogenase, 389
ALDH, 389
Allopregnanolone, 987
Alzheimer's disease, 457
Amide bond, 7
Amino acids, 779
Amphetamine, 299, 379, 767
Analgesia, 1
Analgesics, 943
Anesthesia, 111
Angiotensin II, 23
Animal model, 7, 355
Aniracetam, 45
Antagonist, 291
Anticonvulsant, 965
Antidepressant effect, 39
Antidepressant, 411
Antinociception, 267
Antisense, 617
Anxiety, 131, 179, 437, 449, 543, 643, 681, 913, 931, 993
AP5: MK-801, 251
Arachidonic acid release, 29
L-arginine, 515
Ascorbic acid, 811
Ataxia, 107, 125
Atropine, 197
Attention, 681, 795, 953
Atypical antipsychotic, 767
Auditory perception, 1
Autoshaping, 507
Aversion, 659
Aversive brain stimulation, 761
Avoidance learning, 13
Baboon, 1
Basal forebrain, 209, 899
Beam-walking, 899
Bed nucleus of stria terminalis, 213
Beedies, 443
Behavior, 335
Behavioral model, 371
Behavioral stress, 707
Benzodiazepine receptor, 411
Bidis, 443
Bilateral asymmetry, 189
Binge drinking, 521
Blood pressure, 811, 847
Body shakes, 371
Body temperature, 865
Body weight, 423
Brain, 237
BTCP, 343
Butea monosperma, 965
C57BL/6 mice, 13
Cadmium, 581
Caffeine, 811
Calmodulin, 189
Candy, 729
Cannabis, 811
Castration, 717
Catalase, 389
Catalepsy, 197
Catecholamines, 847
CCK, 403
Cerebellum, 237
Cerebral cortex, 779
Cholinergic and dopaminergic systems, 45
Cholinergic, 953
Chronic mild stress, 465
Chronic stress, 723
Chronic use, 237
Cimetidine, 437
Ciproxifan, 741
Clonidine, 979
CNS, 229
Cocaine, 1, 171, 343, 431, 633, 651, 803, 857, 873, 931
Cognition, 865
Cognitive deficits, 591
Cognitive dysfunction, 521
Cognitive performance, 707
Colonic temperature, 93
Compound 48/80, 437
Conditioned aversions, 931
Conditioned place preference, 101

- Conditioned place preference, 931
 Conditioned taste aversion, 551, 633
 Conditioning, 65, 107, 171
 Context conditioning, 795
 Context, 107
 Contextual fear, 551
 Convulsions, 515
 Coping, 811
 Copulation, 65
 Copulatory behaviour, 717
 Core temperature, 669
 Corticosterone, 507, 993
 Cortisol, 707
 Crab, 251
 Crack cocaine, 431
 Craving, 559
 CREB, 913
 CRF, 993
 CRH, 993
 Cross-sensitization, 101
 Cross-tolerance, 101
 Crustacea, 251
 Current intensity, 847
 Cyanamide–ethanol reaction (CER), 389
 Cyanamide, 389
 Cyclosporin A, 267
 Cytoskeleton and GABA_A receptors, 497

 D2 receptor, 803
 D3 dopamine receptors, 623
 D₁ receptor, 723
 DBA/2 inbred mice, 659
 Defeat, 131
 Defensive burying behavior, 543
 Delayed nonmatching to position, 319
 Dependence, 87
 Depleted uranium (DU), 881
 Depression, 131, 355, 465, 723
 Designer drugs, 299, 307, 379
 Desipramine, 39
 Development, 591
 Developmental, 581
 1,4-DHP calcium channel blockers, 93
 5,7-DHT, 899
 5,7-Dihydroxytryptamine, 979
 Diabetic mice, 365
 Diazepam, 13, 543
 Dipsogenia, 741
 Discrete fear, 551
 Discrimination, 1
 Distance, 73
 DOI, 371, 761

 Dopamine reuptake inhibitor, 343
 Dopamine, 7, 65, 617, 717, 811, 857
 Dopamine; Serotonin, 987
 Dopaminergic neuron, 723
 Dorsal periaqueductal gray, 761
 Drinking behavior, 1
 Drug discrimination, 29, 77, 767
 Drug reward, 931
 Dry mouth, 117

 Early follicular phase, 431
 Early postnatal handling, 221
 EGb, 761, 913
 Electrical kindling, 965
 Elevated plus-maze, 449, 543, 973, 913
 Endogenous opioids, 101
 β-endorphin, 601
 Epinephrine, 847
 ERPs; Event-related potentials, 457
 Escalation, 873
 Estradiol valerate, 601
 Estradiol, 313, 601
 Estrogen, 313, 601
 Ethanol preexposure, 787
 Ethanol self-administration, 787
 Ethanol tolerance, 291
 Ethanol, 55, 213, 389, 483, 601, 633, 699
 Ethanol-induced hyperlocomotion, 787
 Ethanol/cocaine combinations, 787
 Ethological analysis, 973
 Exploration, 335
 Extended amygdala, 213
 Extinction, 623, 729

 Feeding, 403
 Females, 533
 Fenfluramine, 77
 Fentanyl, 873
 Fever, 143
 Fischer rats, 533
 Fixed ratio, 343
 Flat body posture, 533
 Flavor, 559
 Fluid deprivation, 1
 Food intake, 423
 Foot-shock pain threshold, 13
 Forced swim, 335
 Forced swimming test, 39, 411
 Freezing, 795
 Fruit-drink, 729
 Functional observational battery, 835

 G-proteins, 273
 GABA mimetics, 111
 GABA receptor antagonists, 111
 GABA uptake inhibitors, 111
 GABA, 111, 937
 GABA_A receptor recruitment and phosphorylation, 497
 GABA_A receptors, 923
 GABA_A–benzodiazepine receptor, 179
 Gamma aminobutyric acid, 515
 Gender differences, 13, 691, 707
 General anesthetics, 111
Ginkgo biloba, 913
 Ginseng total saponin, 1
 Gonadal hormones, 221
 GT-2331, 741

 Hallucinogens, 29, 307, 379, 65
 Halothane, 937
 Head bobs, 371
 Heart rate, 847
 Heroin, 313
 Hippocampus, 237, 779, 913
 Histamine H₃ receptors, 741
 Histamine, 751
 Hot plate test, 751
 5-HT, 291, 761
 5-HT_{1A} receptor, 403
 5-HT_{1A} receptor antagonist, 465
 5-HT_{2A} receptor, 29, 371, 397
 5-HT_{2B/2C} receptors, 1
 5-HT_{2C} receptor, 371
 Human, 237
 Hyperosmolarity, 1
 Hyperthyroidism, 643
 Hypothalamus, 189
 Hypothermia, 93, 143
 Hypothyroidism, 643
 Hypovolemia, 1

 192 IgG-saporin, 899
 Imipramine, 397, 411, 761
 Incentive motivation, 623
 Incentive, 65
 Indomethacin, 143
 Intracranial self-administration, 55
 Intraperitoneal injections, 987
 Intravenous ethanol, 787
 Intravenous, 313, 873
 Inverse agonist, 741
 Isoproterenol, 817

 Ketanserin, 77

- Lateral septum, 817
 Learning, 107, 251, 795
 Lever release, 1
 Light/dark test, 437
 α -Linolenic acid, 7
 Liquid diet, 213
 Lithium–pilocarpine, 965
 Lithium, 131, 397
 Locomotion, 117, 171
 Locomotion, 899
 Locomotor activity, 73, 475, 659
 Long-term effects, 795
 Lordosis behavior, 533
- Male rats, 543
 Male sexual behavior, 937
 MAO-B, 617
 Marijuana, 237
 Mast cell-deficient (W/W^v) mice, 437
 Maximum electroshock, 965
mCPP, 1
 MDMA, 299, 379, 617
 Mealtime-associated circadian anticipation, 45
 Mecamylamine, 319
 Melanocortin receptor autoradiography, 491
Melissa officinalis, 953
 Memory acquisition, 417
 Memory retrieval, 417
 Memory, 209, 237, 251, 681, 899, 953
 Menstrual cycle, 431
 Methyl β -carboline-3-carboxylate, 411
 4-Methylpyrazole, 389
 4-MP, 389
 Methylphenidate, 651
 Mice, 23, 197, 203, 389, 779, 987, 993
 Microdialysis, 213, 617
 Micronized progesterone, 431
 Midazolam, 973, 987, 993, 449
 Middle cerebral artery occlusion, 569
 MMAI, 77
 MMN, 457
 Mode of action, 45
 Monoamines, 779
 Mood, 681, 707, 953
Morinda officinalis, 39
 Morphine adrenoceptor agonists, 203
 Morphine and reproduction, 157
 Morphine concentrations in blood and brain, 691
 Morphine, 87, 101, 197, 581, 979
- Morphine- and VS-induced analgesia, 165
 Morphine, 691
 Morris water maze, 417
 Morris water task, 591
 Motivation, 65
 Motor activity, 993
 Motor, 899
 Mouse, 179, 319, 411, 741, 751
 Muscarinic acetylcholine receptor, 881
- Naloxone, 197, 267, 601, 699, 87, 979
 Naltrexone, 483
 6- β Naltrexol, 483
 L-NAME, 143, 515
 Nerve agents, 835
 Neurodegeneration, 521
 Neuroprotection, 569
 Neurosteroids, 923
 Neurotoxicity, 881
 Nicotine addiction, 707
 Nicotine concentrations, 279
 Nicotine gum, 559
 Nicotine replacement therapy, 279
 Nicotine, 197, 279, 355, 457, 559
 Nicotinic antagonists, 197
 Nitric oxide, 229, 267, 515, 881
 NMDA antagonist, 873
 NMDA, 251, 291
 Noolit, 131
 Norepinephrine, 817, 847
 Norfenfluramine, 77
 NOS inhibitor, 873
- Olanzapine, 767
 8-OH-DPAT, 403, 761, 171
 One trial tolerance, 449, 973
 Open arm avoidance, 449
 Open field, 73, 221, 171
 Operant behavior, 39
 Operant responding, 923
 Opiate physical dependence, 691
 Opiate withdrawal; gender differences, 691
 Opiate, 87
 Opiates and reproduction, 157
 Opiates, 157
 Opioid tolerance, 273
 μ -Opioid down-regulation, 273
 κ -opioid receptor agonists, 93
 Opponent-Process Theory, 931
 Organophosphate, 669, 835
 Osmotic mini-pumps, 943
 Ovariectomy, 313
- Pain, 751
 Panic disorder, 761
 Parkinson's disease, 7
 Paternal influences, 157
 Paternal opiate administration, 157
 Pavlovian, 507
 PCP, 125
 Pentylentetrazol, 965
 Pertussis toxin, 273
 Pharmacological activity, 943
 Phosphoinositide hydrolysis, 29
 Picrotoxin, 515, 987
 Pilocarpine, 229
 Place conditioning, 87, 659
 Place learning, 551
 Placebo-alcohol, 151
 Plus maze test, 643
 PMMA, 379
 Positron emission tomography, 237
 Potentiation, 1
 Prandial, 117
 Prazosin, 365
 Preference, 659
 Prefrontal cortex, 237, 723
 Pregnanolone, 543
 Prenatal antipsychotics, 575
 Prenatal morphine exposure, 165
 Prenatal morphine, 221
 Priming, 729
 Proactive interference, 319
 Progesterone, 431, 543
 Progressive ratio, 343
 Progressive-ratio schedule, 803
 Proopiomelanocortin, 491
 Propranolol, 817
 Proxyfan, 741
 Pups, 993
- Quinpirole, 591
 Quipazine, 77
- Rabbit, 371
 Radial arm maze, 209, 865
 Radial maze, 899
 Raphe, 899
 Rat brain, 291
 Rat, 143, 209, 335, 551, 643, 717, 723, 857, 923, 943
 Rats, 125
 Rats, 507, 575, 633
 Re-instatement, 623
 Reaction time, 1
 Regional cerebral blood flow, 237
 Reinforcement, 55, 923
 Reinforcing effect, 803
 Reinstatement, 729

- Relapse, 729
Reproductive function, 157
Response-independent, 729
Restraint, 335
Reversal learning, 521
Rhesus monkey, 729
 θ rhythm, 669
Ricinine, 779
Righting reflex, 111
Ritalin, 651
- Rotarod performance, 723
- Salivary secretion, 229
Salivation, 117
Sarin, 835
Scopolamine, 319
Second-order schedule, 729
Seizures, 117, 779, 987
Self-administration, 279, 313, 343, 623, 699, 803, 873, 923
Sensitization, 125, 581, 623, 651, 659, 873
Sensorimotor, 881
Sensory contact model, 131
Sensory memory, 457
Serotonergic neurotoxicity, 617
Serotonin metabolism, 403
Serotonin syndrome, 533
Serotonin, 1, 77, 979
Sex differences, 335, 681
Sex, 857, 899
Sexual behavior, 533, 817
Sexual differentiation, 189
Signal detection, 319
Sildenafil, 717
SKF 81297, 723
Skilled reaching, 591
- Sleep–wake, 669
Smoking, 443, 681
Social drinkers, 151
Social interaction test, 643
Social stress, 131
Spatial information, 417
Spatial memory, 319, 913
Speed, 73
Sperm motility, 937
Spindles, 669
Spontaneous locomotor activity, 365
Sprague–Dawley rats, 533
SSRI, 465
Stimulant abuse, 767
Stimulant drugs, 931
Stimulant effects, 151
Stimulants, 307, 379
Strain comparison, 319
Strain, 179
Stress and GABA_A receptor, 497
Stress reaction, 847
Stress response, 335
Stress, 681, 811, 993
Stress-induced hyperthermia, 179
Stroke, 569
Subcutaneous continuous infusion, 943
Sucrose, 423, 483
Suppression of drinking, 699
Sympathetic nerve, 847
Sympathoneural, 847
- T-maze, 899
Tacrine, 457
Tail suspension test, 411
Tail-flick test, 267
Tamoxifen, 189, 417
Taste aversion, 87
- Taste avoidance, 87
Temperature, 179
Temporal regulation of behavior, 45
Test meal, 423
Testosterone, 189, 717
Thioperamide, 437
Tobacco, 811
Tolerability, 943
Tolerance, 1, 107, 125, 873
Toremifene, 417
Tumor necrosis factor- α , 143
Two-bottle choice, 923
Tyrosine, 7
- U-50,488H, 1
UCS preexposure, 633
Ultrasonic vocalization, 993
Uranyl acetate, 881
- Ventral pallidum, 209
Ventral tegmental area, 55
- Waking immobility, 669
Water maze, 73, 899
Wet-dog shake, 397
Wheel running, 101
Whishaw reaching task, 591
Withdrawal syndrome, 979
Withdrawal, 213, 707, 87
Working memory, 319, 575, 865
Writhing test, 23, 751
Yin and Yang, 847
Yohimbine, 817
Zucker rat, 403